King Luther Capital Management Corp Has $16.57 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• King Luther Capital Management Corp increased its holdings in DexCom, Inc. by 9.2% in Q1, purchasing an additional 20,518 shares, bringing its total to 242,650 shares valued at approximately $16.57 million.
• Other institutional investors, including Vanguard Group and Jennison Associates, also significantly increased their positions in DexCom during the first quarter, further solidifying institutional ownership at 97.75%.
• DexCom reported earnings of $0.48 EPS for the last quarter, surpassing estimates, with a revenue of $1.16 billion, marking a 15.2% increase year-over-year.

King Luther Capital Management Corp increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 9.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 242,650 shares of the medical device company's stock after purchasing an additional 20,518 shares during the period. King Luther Capital Management Corp owned 0.06% of DexCom worth $16,571,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Golden State Wealth Management LLC grew its position in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in DexCom during the first quarter worth $27,000. Optiver Holding B.V. acquired a new position in DexCom during the fourth quarter worth $33,000. Heck Capital Advisors LLC purchased a new stake in DexCom in the 4th quarter valued at $38,000. Finally, Alpine Bank Wealth Management purchased a new position in shares of DexCom during the 1st quarter worth $40,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of NASDAQ:DXCM remained flat at $79.96 on Thursday. The stock had a trading volume of 2,233,756 shares, compared to its average volume of 3,910,180. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The firm has a market capitalization of $31.36 billion, a P/E ratio of 55.53, a PEG ratio of 1.68 and a beta of 1.43. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The business has a 50-day moving average of $83.28 and a 200 day moving average of $80.19.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The business's quarterly revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.43 earnings per share. As a group, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the sale, the executive vice president directly owned 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the transaction, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 28,656 shares of company stock valued at $2,412,191. 0.32% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on DXCM shares. Mizuho boosted their price objective on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Wall Street Zen downgraded shares of DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday. UBS Group raised their price target on DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Robert W. Baird decreased their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Finally, Piper Sandler lifted their target price on DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a research report on Thursday, July 31st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.